Protagonist Therapeutics Q4 2023 Earnings Report $48.20 +1.32 (+2.82%) As of 04:00 PM Eastern Earnings HistoryForecast Protagonist Therapeutics EPS ResultsActual EPS$0.44Consensus EPS $0.05Beat/MissBeat by +$0.39One Year Ago EPSN/AProtagonist Therapeutics Revenue ResultsActual Revenue$60.00 millionExpected Revenue$60.00 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AProtagonist Therapeutics Announcement DetailsQuarterQ4 2023Date2/27/2024TimeAfter Market ClosesConference Call ResourcesPress ReleasePTGX Earnings HistoryPowered by Remove Ads Protagonist Therapeutics Earnings HeadlinesProtagonist Therapeutics (NASDAQ:PTGX) Given "Outperform" Rating at WedbushMarch 30 at 2:42 AM | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), Tyra Bioscience (TYRA)March 28, 2025 | markets.businessinsider.comPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.April 2, 2025 | Brownstone Research (Ad)Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?March 18, 2025 | msn.comIs Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment?March 15, 2025 | insidermonkey.comJ.P. Morgan Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)March 13, 2025 | markets.businessinsider.comSee More Protagonist Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Protagonist Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your email. Email Address About Protagonist TherapeuticsProtagonist Therapeutics (NASDAQ:PTGX), a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.View Protagonist Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
